0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe [Skyrizi]1 ML risankizumab-rzaa 150 MG/ML Auto-Injector [Skyrizi]
View 4 more
NO BLACK BOX WARNING
Dosage & administration
Recommended Dosage
Plaque Psoriasis and Psoriatic Arthritis:
Crohn’s Disease:
* Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI.
* The recommended induction dosage is 600 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage to maintain therapeutic response.
Most viewed Skyrizi resources
Billing and Coding Guide
Coverage Authorization Request - Rheumatology
Coverage Authorization Appeal - Rheumatology
Letter of Medical Necessity - Rheumatology
View more
drug label
Skyrizi prescribing information
Have more Skyrizi questions?
Submit MSL Request
Learn More
Your request will be referred to the appropriate AbbVie Inc. medical professional, such as a Skyrizi pharmaceutical rep; Medical Science Liaison (MSL) or medical affairs.
Need to report a Skyrizi issue?
ONLINE FORMReport adverse event
Learn More
You can report a Skyrizi adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
prior authorization
Skyrizi Prior authorization resources
NOT PROVIDED BY BRANDComplete Letter of Medical Necessity
NOT PROVIDED BY BRANDComplete Coverage Authorization request
NOT PROVIDED BY BRANDComplete Coverage Authorization appeals
Coverage Authorization Request - Rheumatology
Coverage Authorization Appeal - Rheumatology
Letter of Medical Necessity - Rheumatology
Coverage Authorization Request - Dermatology
Coverage Authorization Appeal - Dermatology
Letter of Medical Necessity - Dermatology
Coverage Authorization Request - Gastroenterology
Learn More
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
Enrollment Form - Rheumatology & Dermatology
Enrollment Form - Gastroenterology
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
Receive Assistance from an FRM Regarding Reimbursement Information
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Skyrizi Financial assistance options
Co-pay savings program
commercial only
Enroll in patient savings program
Learn More
Overview
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
commercial only
Enroll in Bridge Program
Learn More
Overview
Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
100% free (outside of insurance)
Patient eligibility
HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
Typically HCP assisted enrollment (via form)
Foundation programs
under insured
no insurance
goverment insurance
65+
Abbvie Patient Assistance Program Application - English
Abbvie Patient Assistance Program Application - Spanish
Learn More
Overview
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Skyrizi Patient education
Getting started on Skyrizi
Instructions For Use -Plaque Psoriais
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Instructions For Use - Psoriatic Arthritis
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Instructions For Use - Crohn's Disease
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Patient toolkit
About Skyrizi - Plaque Psoriasis
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Before and After - Plaque Psoriais
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
About Skyrizi - Psoriatic Arthritis
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
About Skyrizi - Crohn's Disease
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
people also ask
Skyrizi FAQs
Is there a pregnancy exposure registry for SKYRIZI?Yes, there is a pregnancy exposure registry for SKYRIZI that monitors outcomes in women who become pregnant while treated with the medication. Patients can enroll by calling 1-877-302-2161 or visiting http://glowpregnancyregistry.com.
What is the risk of using SKYRIZI during pregnancy?Available data on risankizumab use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. However, monoclonal antibodies can be actively transported across the placenta, and SKYRIZI may cause immunosuppression in the in utero-exposed infant. Additionally, there are adverse pregnancy outcomes in women with inflammatory bowel disease.
What is the background risk of birth defects and miscarriage in the general population?In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Is SKYRIZI detected in human milk?There is no data on the presence of risankizumab in human milk. However, maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SKYRIZI and any potential adverse effects on the breastfed infant from the medication or from the underlying maternal condition.
Is SKYRIZI safe and effective in pediatric patients?The safety and efficacy of SKYRIZI in pediatric patients (less than 18 years of age) have not been established.
Is there a difference in safety and efficacy of SKYRIZI between older and younger subjects?Of the subjects with plaque psoriasis or psoriatic arthritis exposed to SKYRIZI, a total of 185 subjects were 65 years or older, and 13 subjects were 75 years or older. No overall differences in safety or effectiveness were observed between older and younger subjects who received SKYRIZI. However, the number of subjects aged 65 years and older was not sufficient to determine whether they respond differently from younger subjects.
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.